According to The Fly, in a latest note to investors, a research analyst has provided a rating update for the Healthcare company, Aurinia Pharma (AUP – Research Report). Cantor Fitzgerald’s analyst Elemer Piros reiterates their Buy rating on the shares today.
“We rate Aurinia Pharmaceuticals Overweight. Aurinia is developing a cyclosporine drug analog, voclosporin, for the treatment of lupus nephritis. Voclosporin is the first development candidate to achieve a successful primary readout in a large global randomized trial for lupus nephritis. Aurinia is conducting a single pivotal Phase 3 AURORA study, which completed enrollment in September 2018. To-date, there remains no approved therapy for lupus nephritis in the U.S.”
According to TipRanks.com, Piros is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -6.0% and a 41.1% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Proteostasis Therapeutics Inc, and Strongbridge Biopharma Plc.
The the analyst consensus on Aurinia Pharma is currently a Moderate Buy rating.
The company has a one-year high of C$8.65 and a one-year low of C$5.68. Currently, Aurinia Pharma has an average volume of 32.36K.
Aurinia Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
The company’s shares closed on Thursday at C$7.36.